MRNA vaccine for recurrent high-grade glioma
Part of Cancer clinical trials.
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade glioma (WHO Grade 3 or 4) that has come back or gotten worse after standard treatment.
- Your tumor must have one of these specific gene changes: H3.3K27M, H3.1K27M, H3.3G34R, BRAF V600E, PIK3CA H1047R, IDH1 R132H, or EGFRvIII.
- You are at least 16 years old and in generally good health (kidney, liver, heart, and blood counts are within safe limits).
- You are not taking high doses of steroids (dexamethasone ≤2 mg/day) and do not have a severe infection or other active cancer.
- You agree to use effective birth control if you could become pregnant or father a child, for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
This trial tests a new personalized RNA vaccine made from your own tumor tissue. It is designed to help your immune system fight the cancer after it has returned. You will have surgery to collect the tumor, and then the vaccine is given to try to stop the tumor from growing again.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
This trial tests a vaccine made from your own immune cells (dendritic cells) to see if it can help control recurrent or progressive high-grade gliomas. It is for people whose brain tumor has returned after standard treatments.
This trial tests a personalized vaccine created by AI to target your specific brain tumor. It is for people with a glioma that came back after standard treatments like surgery, radiation, or chemotherapy, and whose tumor has enough genetic mutations to make the vaccine.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to treat glioblastoma that has come back after standard treatment. The vaccine is designed to help your immune system recognize and attack your tumor.
Hear when a new Glioma, High Grade trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.